News | May 20, 2009

Edwards Announces First Human Implants With 18 French Transcatheter Valve

May 21, 2009 – Edwards Lifesciences Corp. last week announced the successful completion of the first human implants of its next-generation transcatheter aortic heart valve used with its new 18 Fr. delivery system.

Edwards expects these cases, performed in Canada, to be reviewed this week at EuroPCR 2009. The 18 Fr. system features the Edwards SAPIEN XT valve paired with its new, smaller NovaFlex transfemoral delivery system. The valve has a cobalt chromium alloy balloon-expandable frame, which allows for a significant reduction in its profile, and bovine pericardial tissue leaflets processed in the same stringently controlled manner as Edwards' market-leading surgical heart valves. The NovaFlex delivery system leverages the ease-of-use features of the Edwards RetroFlex line of delivery systems.

"The clinical success of the Edwards SAPIEN valve has allowed us to treat patients who previously had no good treatment options. The new Edwards SAPIEN XT valve, with its improved design and revolutionary lower profile delivery system, will allow us to treat aortic stenosis patients even more reliably and safely," said John Webb, M.D., who performed the first successful human implants of the new transcatheter system. Webb is director of the cath lab and cardiac intervention at St. Paul's Hospital in Vancouver, British Columbia, and a consultant to Edwards Lifesciences.

While the Edwards SAPIEN XT valve is being evaluated in the PREVAIL EU trial for CE mark approval, the commercial rollout of Edwards' RetroFlex 3 delivery system to be used with the Edwards SAPIEN valve is underway in Europe. The RetroFlex 3 delivery system is designed to optimize physician control of valve navigation and facilitate crossing of the patient's native calcified aortic valve.

The Edwards SAPIEN valve is approved for commercial sale in Europe. In the U.S. it is being studied as part of a randomized, pivotal clinical trial.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init